Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Phase 1Recruiting
- Sponsor
- Nurix Therapeutics
- Start
- Apr 2022
- Primary completion
- Jan 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 8
01
Overview
Phase 1, randomised, open-label trial of bexobrutideg in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and 6 more (19 arms), sponsored by Nurix Therapeutics. Primary endpoints: Number of participants with protocol specified dose-limiting toxicities up to 24 months, Maximum tolerated dose and/or recommended Phase 1b dose(s) up to 24 months and 2 more. Started Apr 2022; status: recruiting.
02
Drugs
bexobrutideg
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05131022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131022.